Ederlis SAS

Edelris is a track-proven partner in innovation, working in support to drug discovery organizations. Edelris offers expertize and capabilities in the field of medicinal, organic and high-throughput chemistry, and specifically prepares original, non-exclusive collections of innovative molecules.

  • Keymical Collectionsâ„¢: non-exclusive pseudo-natural products for HTS applications (see for example H.Waldmann et al. Angew. Chem. Int. Ed. 2019, 58, 17016 – 17025)
  • Keymical Fragmentsâ„¢: non-exclusive 3D fragments for fragment-based screening and fast follow-up (see for example C.Jorand-Lebrun et al. Bioorg. Med. Chem. Lett. 2019, 29, 126717)
  • DEL by EDELRIS: DNA-encoded libraries for exclusive clients applications
  • Edelris Discovery ENgine (EDEN): Delivering high-potential hits, fast and patentable, for clients’ biological targets, starting from 1 million compounds deck, designed and prepared at Edelris.

Role in the AntiHelix project

Discovery of small molecule inhibitors of human BLM, RecQ1, RecQ4 and PIF1 DNA helicases.

The AntiHelix Team

Didier RocheESR12 SupervisorDidier.roche@edelris.com
Vincent RodeschiniESR12 TutorVincent.rodeschini@edelris.com
Laure BennejiAdministratorLaure.BENNEJI@edelris.com
Mark WeverESR12Mark.WEVER@edelris.com

Didier Roche

Didier Roche graduated from Strasbourg University (1995) to join Novartis Central Research in Basel, before moving on to Process Research in East Hanover (USA). He then moved to Merck Serono in 2000 as a project leader responsible for medicinal chemistry and parallel synthesis programs. Strongly implicated in different research projects in the diabetes field, he became Head of the Merck Serono Medchem department in Paris, with wide-ranging responsibilities in Discovery and pre-clinical development. During his tenure he acquired a broad expertise in asymmetric synthesis, medicinal chemistry, chemo-informatics and Discovery project management.

Within the AntiHelix consortium he has a role as supervisor of ESR12, member of the Supervisory Board, member of the Exploitation Committee, and co-organiser of training courses.

Vincent Rodeschini

Vincent Rodeschini obtained his Ph.D. from the University of Haute Alsace in 2004 (Prof J. Eustache), where he worked on the synthesis of analogs of natural product Fumagillin as angiogenesis inhibitors. He then moved to Nottingham, UK, for a postdoctoral position in the laboratory of Pr. N. Simpkins (Marie Curie fellowship). There he works on the field of chiral base driven deprotonation and natural product synthesis (Garsubellin). Following a first position at Novexel in the field of antibiotics, he joined Edelris in 2007, where he is currently senior project leader in the medicinal chemistry unit. He has acquired a broad expertise in synthetic and medicinal chemistry as well as in structure based drug design.

Within the AntiHelix consortium he has a role as tutor of ESR12.

Mark Wever

Mark Wever received a Bachelor Degree with distinction in Liberal Arts and Sciences with a specialization in Chemistry from Amsterdam University College (NL). He then pursued a master Degree in Drug Discovery and Safety with a specialization in ‘Drug Design & Synthesis’, and graduated from the Vrije Universiteit Amsterdam (NL) in 2020. He has successfully completed his master research project in Medicinal Chemistry at the Vrije Universiteit (7 months, 2018) and an additional internship at Janssen Pharmaceutica (8 months, 2019).

He has joined the AntiHelix Consortium as ESR12, working on the discovery of small molecule inhibitors of human helicases through computer-aided methods and synthesis.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 859853